<DOC>
	<DOCNO>NCT00097513</DOCNO>
	<brief_summary>This study multicenter , open-label , observational , postmarketing surveillance study collect information use Genentech GH preparation treat GH-deficient subject optimal GH dose puberty .</brief_summary>
	<brief_title>National Cooperative Growth Study ( NCGS ) Optimal Nutropin AQ Nutropin Dosing Pubertal Growth Hormone-Deficient ( GHD ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Dwarfism</mesh_term>
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Adolescent boys GH deficient Tanner Stage 2 great ( testes 3 mL great ) Adolescent girl GH deficient breast Tanner Stage 2 great Current treatment GH dose 0.4 0.7 mg/kg/wk Ability keep followup appointment throughout study Willingness remain therapy epiphyseal closure achieve Prior enrollment NCGS Core Study 85036 Treatment nonGenentech GH preparation Closed epiphysis Active neoplasia Treatment insulin diabetes</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Pubertal Growth Hormone Deficiency</keyword>
</DOC>